Shire (New River Pharmaceuticals)
GPTKB entity
Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:New_River_Pharmaceuticals
|
| gptkbp:acquisitionYear |
2007
|
| gptkbp:ceased_operations |
2019
|
| gptkbp:focusArea |
neuroscience
internal medicine regenerative medicine rare diseases gastrointestinal diseases |
| gptkbp:founded |
1986
|
| gptkbp:headquartersLocation |
gptkb:Dublin,_Ireland
|
| https://www.w3.org/2000/01/rdf-schema#label |
Shire (New River Pharmaceuticals)
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:mergedInto |
gptkb:Takeda_Pharmaceutical_Company
|
| gptkbp:notableProduct |
gptkb:Vyvanse
Adderall XR |
| gptkbp:parentCompany |
gptkb:Takeda_Pharmaceutical_Company
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:stockExchange |
gptkb:LSE
gptkb:NASDAQ |
| gptkbp:bfsParent |
gptkb:Randal_J._Kirk
|
| gptkbp:bfsLayer |
7
|